Impax Laboratories and Tolmar will collaborate on a multiproduct agreement for the development, supply and distribution of generic topical prescription drug products. Tolmar will supply as many as nine currently approved and marketed products, and Impax’s generics division, Global Pharmaceuticals, will commercialize these products following a short transition period. According to Wolters Kluwer Health, total U.S. brand and generic sales of these nine multi-source products were approximately $37...